SAN DIEGO, Jan. 30, 2018 /PRNewswire/ — BioDuro LLC, a leading global life sciences contract research, development and manufacturing organization announced today a cooperation agreement with Porton Pharma Solutions, Ltd. a leading provider of custom, cross life-cycle active pharmaceutical ingredient (API) development and cGMP manufacturing services to the global drug industry.
Under this agreement, BioDuro will promote and market Porton's extensive and proven capabilities for pilot and large-scale GMP production of custom APIs and drug intermediates, while Porton will incorporate BioDuro's comprehensive array of unique technologies and expert resources in drug discovery (from lead compound ID and lead optimization to clinical candidate nomination), and BioDuro's expert formulations development and cGMP manufacture of clinical trial materials (CTMs) into Porton's suite of solutions to address complex process scale-up challenges for IND-enabling studies.
"Our partnership with Porton further expands the reach of our offerings to provide fully integrated API and drug product development and manufacturing solutions to our clients for seamless advancement of their programs from discovery to clinical development," said Cyrus K. Mirsaidi, BioDuro's President and CEO. "Porton's global footprint and proven track record with many of the world's leading pharmaceutical companies will provide substantiated channels for timely and reliable delivery of high value therapeutics, using innovative and cost effective manufacturing routes, backed by high-quality assets in Asia and North America."
"We are very excited about our collaboration with BioDuro as we complement each other's capabilities and share an industry reputation for scientific and technical expertise, excellence in operational performance and a client-centric culture. Together, we can offer our global customers compelling benefits in the form of robustly integrated solutions, compressed drug development timelines and a highly efficient supply chain across the product life cycle," added Oliver Ju, CEO of Porton.
About Porton
Porton is an industry-leading partner and provider of custom Active Pharmaceutical Ingredient (API) development and manufacturing services to the global drug industry (SZSE, Stock Code 300363). Backed by >1,700 customer-centric employees, cutting-edge Process R&D Centers, USFDA and PMDA-inspected cGMP production sites and marketing offices located across Asia, North America and Europe, Porton helps its customers more efficiently deliver improved health outcomes to their patients through chemical process innovation, rapid scale-up and robust, cost-effective manufacture of APIs and/or drug intermediates. Learn more by visiting www.porton.cn
SOURCE BioDuro LLC
